Platelet transfusions carry greater risks of infection, sepsis, and death than any other blood
product, owing primarily to bacterial contamination. Many patients may be at particular risk …

Background Platelet transfusions are used to prevent and treat bleeding in people who are
thrombocytopenic. Despite improvements in donor screening and laboratory testing, a small …

Nowadays patients receiving blood components are exposed to much less transfusion-
transmitted infectious diseases than three decades before when among others HIV was …

Background and Objectives Pathogen inactivation (PI)‐treated plasma and platelets are
increasingly becoming the products of choice, where licensed. This review summarizes the …

BACKGROUND: Continued hemorrhage remains a major contributor of mortality in
massively transfused patients and those who survive have a higher platelet (PLT) count and …

Transfusion-transmitted infections (TTI) have been greatly reduced in numbers due to the
strict donor selection and screening procedures, ie the availability of technologies to test …

Background Platelet transfusions are used in modern clinical practice to prevent and treat
bleeding in thrombocytopenic patients with bone marrow failure. Although considerable …

BACKGROUND Delayed, large‐volume bacterial culture and amotosalen/ultraviolet‐A light
pathogen reduction are effective at reducing the risk of bacterial proliferation in platelet …

Pathogen inactivation of platelet concentrates reduces the risk for blood-borne infections.
However, its effect on platelet function and hemostatic efficacy of transfusion is unclear. We …

Background Platelet transfusions are used in modern clinical practice to prevent and treat
bleeding in people who are thrombocytopenic due to bone marrow failure. Although …